Alchemab Therapeutics enters $415 million licensing agreement with Eli Lilly for ATLX-1282: Cambridge, UK Wednesday, May 7, 2025, 12:00 Hrs [IST] Alchemab Therapeutics (Alchemab), ...

Prilenia, Ferrer entered collaboration agreement for commercialization and co-development of pridopidine in Europe and other ...

Wade Leming was diagnosed with this degenerative disease. His friends and family created a tradition called Wade's Day that ...

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Houston mortgage duo Cissy and Christopher Larkin are channeling a four-year ALS battle into a widespread fundraiser.

Lilly licenses Alchemab’s ALS antibody ATLX-1282 in $415mn deal, expanding its neuroscience pipeline with a novel, ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Learn more about whether argenx SE or Exact Sciences Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In a remarkable achievement, a paralyzed and nonverbal patient with a Neuralink chip was able to edit a video using only his brain signals.

Financial terms of the new agreement include an upfront payment to secure rights to Alchemab's lead ALS candidate, ATLX-1282, ...

Eli Lilly (LLY) inks a licensing agreement with Alchemab to jointly develop an ALS drug in a $415M deal. Read more here.